Navigation Links
AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/8/2013

o the third quarter of 2014.

Conference CallAcelRx will conduct a conference call and webcast today, May 8, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its financial results and program updates.  To listen to the conference call, dial in approximately ten minutes before the scheduled call to (800) 860-2442 for domestic callers, (866) 605-3852 for Canadian callers, or (412) 858-4600 for international callers.  Those interested in listening to the conference call live via the Internet may do so by visiting the Investors section of the company's website at www.acelrx.com and selecting the Webcast link for the Q1 2013 earnings conference call.  A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investors section of the company's website at www.acelrx.com.

About AcelRx Pharmaceuticals, Inc. AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.  AcelRx's lead product candidate, the Sufentanil NanoTab PCA System, or NanoTab System, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps.  AcelRx has announced results from two Phase 3 clinical trials for the NanoTab System, and a third Phase 3 study has completed enrollment, with data expected in the second quarter of 2013.  A New Drug Application submission is planned for the third quarter of 2013. AcelRx recently announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant f
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
2. AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
3. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
4. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
5. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
6. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
7. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. AcelRx Pharmaceuticals Provides Clinical Trial Updates
9. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
10. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
11. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Increasing unnecessary regulations on drug plans could inflict higher ... medications through a managed drug plan, according to a ... Analysis Senior Fellow Devon Herrick. "The ... helps makes medications affordable," says Herrick. "Blatant protectionism through ... protections, but more often than not they are designed ...
(Date:4/20/2015)... 20, 2015 Stand Up To Cancer (SU2C) and the ... million Dream Team to attack the number one cancer killer ... of the American Association for Cancer Research (AACR), Scientific Partner ... in the United States will be ... will die from it, making lung cancer the leading cause ...
(Date:4/20/2015)... 2015 Eli Lilly and Company (NYSE: ... was statistically superior to placebo in the treatment of ... the proportion of patients achieving an ACR 20 response. ... 20 percent reduction in disease signs and symptoms as ... During the 24-week, Phase 3 study, titled SPIRIT-P1, patients ...
Breaking Medicine Technology:Restrictive Drug Plan Regulations Will Hurt Patients 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 3New SU2C-American Cancer Society Lung Cancer Dream Team Announced 4New SU2C-American Cancer Society Lung Cancer Dream Team Announced 5New SU2C-American Cancer Society Lung Cancer Dream Team Announced 6Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 2Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 3Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 4
... QUEBEC CITY, Oct. 2 /PRNewswire-FirstCall/ - AEterna Zentaris ... biopharmaceutical company focused on,endocrine therapy and oncology, today ... patient recruitment for its Phase 2 trial in ... agonist,linked to doxorubicin. The decision to enter the ...
... integrated neurohormonal ... to obesity pharmacotherapy, SAN DIEGO, Oct. 1 Amylin ... for its pipeline obesity,candidates will be presented at the 2008 ... The Obesity Society,s annual,meeting is one of the largest and ...
Cached Medicine Technology:AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7
(Date:4/20/2015)... April 20, 2015 Western Connecticut ... DNP, RN, NEA-BC, FAAN who was named The ... and Research in September 2014, is transitioning from ... to lead the development of Western Connecticut Health ... created role, Donahue will be responsible for the ...
(Date:4/20/2015)... NJ (PRWEB) April 20, 2015 The normal ... stroke. There’s nothing more we could do.” Especially if the ... , Today, the response should be much different. So it’s ... question: “What more can be done?” , Not every ... “There is something that can be done.” But, according to ...
(Date:4/20/2015)... 2015 America’s Health Insurance Plans ... insurance industry, is seeking greater regulation of medical ... involving surgical tools called power morcellators ( http://www.morcellatorlawsuit2015.com ... Casey (D-PA) dated April 14th, the group asserted ... to “serious gaps in the current approval and ...
(Date:4/20/2015)... Mesa, CA (PRWEB) April 20, 2015 ... on TROY Secure Print Enterprise (TSPE) software, which provides ... Michigan on Wednesday, May 6 at the Anthem Suite ... Street from 7 to 11 AM. , Beginning at ... breakfast. Starting at 8 AM, TROY Healthcare Solutions will ...
(Date:4/20/2015)... Today the members of the new Stand ... Alliance-National Ovarian Cancer Coalition Translational Research Dream Team ... “DNA Repair Therapies for Ovarian Cancer,” building on ... a common weakness in ovarian cancer. Researchers will ... ovarian cancer by developing a web-based approach to ...
Breaking Medicine News(10 mins):Health News:Nursing Executive to Develop and Lead Nursing Leadership Program at Western Connecticut Health Network 2Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 2Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 4Health News:TROY Healthcare to Offer Prescription Solutions that Could Save a Health System $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that Could Save a Health System $100,000 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 2Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 4
... March 19 The Pennsylvania,Breast Cancer Coalition (PBCC) will ... at the University of Pennsylvania in the Flyers-76ers,Surgery Theatre ... and Spruce,Streets, to publicize this year,s Income Tax Check-Off ... the eight researchers,who have been selected to receive research ...
... Association Developing New Internet Drug Distributor Identification,Program, ... are now only second to marijuana in the ... street drugs, prescription drugs are,just as dangerous when ... the supervision of a health care practitioner. So ...
... ARLINGTON, Va., March 19 Yesterday,bipartisan groups of ... and,17 U.S. Senators sent letters to the Centers ... the impact of a new Medicare,competitive bidding program ... ask CMS to release data on how the ...
... Chemically altered form of natural compound found in heparin ... health officials say they,ve identified the contaminant found in ... of allergic reactions and possibly 19 deaths in the ... called oversulfated condroitin sulfate, but U.S. Food and Drug ...
... To accommodate rapid growth and,further enhance PRA,s ability to ... office to a larger, more centrally located,facility. By more ... new,location includes more offices and conference and meeting spaces, ... clinical operations,staff while allowing for future expansion of the ...
... (Kingston, ON) Determining how the HIV/AIDS epidemic increases ... be done to reduce the chances of this happening ... , Both Canadian and Southern African expertise ... in policy advocacy around this crucial issue. , Funded ...
Cached Medicine News:Health News:The Pennsylvania Breast Cancer Coalition Announces Event at the University of Pennsylvania Hospital to Celebrate the 2008 Income Tax Check-Off Campaign 2Health News:NABP Supports White House's Commitment to End Illegal Internet Drug Sales 2Health News:Medicare Bidding Program for Durable Medical Equipment May Harm Small Businesses and Decrease Patient Access to Care, Say 137 Members of Congress 2Health News:Medicare Bidding Program for Durable Medical Equipment May Harm Small Businesses and Decrease Patient Access to Care, Say 137 Members of Congress 3Health News:FDA Identifies Contaminant in Blood-Thinning Drug 2Health News:FDA Identifies Contaminant in Blood-Thinning Drug 3Health News:PRA International Announces New Office Opening in Mumbai 2Health News:Food insecurity linked with HIV/AIDS in Africa 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: